Oppenheimer MS survey: Is the 18.6% figure the average of all of the surveyed neurologists or the average of the 73% who think Gilenia will have an impact?The latter. It will drop much more than that if the FDA approves generic Copaxone :- )Let's say gilenia is a more real and immediate threat shall we? Plus I'm willing to negotiate on the "real"part :-)
